Featured Research

from universities, journals, and other organizations

Breast cancer recurrence defined by hormone receptor status

Date:
October 1, 2012
Source:
BioMed Central Limited
Summary:
Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status. New research shows that women whose HER2 positive cancer was also hormone (estrogen and progesterone) receptor (HR) negative had an increased risk of early death, and that their cancer was less likely to recur in bone than those whose cancer retained hormone sensitivity.

Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status. New research published in BioMed Central's open access journal Breast Cancer Research shows that women whose HER2 positive cancer was also hormone (estrogen and progesterone) receptor (HR) negative had an increased risk of early death, and that their cancer was less likely to recur in bone than those whose cancer retained hormone sensitivity.

Breast cancer is a heterogeneous disease with many different subtypes. HR positive cancer is more likely to be luminal A or B type and be treated with endocrine therapy including tamoxifen or aromatase inhibitors, while HR negative cancer is more likely to be basal or 'HER2-enriched'. HER2 positive cancers can fall into both of these categories.

A multicentre study from 13 National Comprehensive Cancer Network (NCCN) hospitals analysed data from over 3000 women diagnosed with early stage HER2 positive breast cancer. At first recurrence, most of the women in the study were treated with chemotherapy and/or with anti-HER2 therapy.

Dr Ines Vaz-Luis, who led the study revealed, "In this large group of patients with HER2 positive breast cancer, we found significant associations between presence of HR and presenting features, patterns of recurrence and survival outcomes. In the first five years after treatment more women died from HR negative cancer than HR positive." Recurrence in the brain or bone was also linked to receptor status, with more HR negative cancer in the brain and HR positive cancer in bone. About half of recurrent tumours tested had switched progesterone or estrogen receptor status (positive to negative or vice versa) or lost HER2 status during the study.

Dr Vaz-Luis, continued, "Based on our findings, HR status defines two different subsets of HER2 positive cancers. To combat this, we believe that studies which look at new drugs for treating HER2-positive breast cancer should also integrate hormone receptor status into their design."


Story Source:

The above story is based on materials provided by BioMed Central Limited. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ines Vaz-Luis, Rebecca A Ottesen, Melissa E Hughes, P Kelly Marcom, Beverly Moy, Hope S Rugo, Richard L Theriault, John Wilson, Joyce C Niland, Jane C Weeks, Nancy U Lin. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Research, 2012; 14 (5): R129 DOI: 10.1186/bcr3324

Cite This Page:

BioMed Central Limited. "Breast cancer recurrence defined by hormone receptor status." ScienceDaily. ScienceDaily, 1 October 2012. <www.sciencedaily.com/releases/2012/10/121001083650.htm>.
BioMed Central Limited. (2012, October 1). Breast cancer recurrence defined by hormone receptor status. ScienceDaily. Retrieved September 16, 2014 from www.sciencedaily.com/releases/2012/10/121001083650.htm
BioMed Central Limited. "Breast cancer recurrence defined by hormone receptor status." ScienceDaily. www.sciencedaily.com/releases/2012/10/121001083650.htm (accessed September 16, 2014).

Share This



More Health & Medicine News

Tuesday, September 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Man Floats for 31 Hours in Gulf Waters

Man Floats for 31 Hours in Gulf Waters

AP (Sep. 16, 2014) A Texas man is lucky to be alive after he and three others floated for more than a day in the Gulf of Mexico when their boat sank during a fishing trip. (Sept. 16) Video provided by AP
Powered by NewsLook.com
Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

AFP (Sep. 16, 2014) Since the arrival of Ebola in Ivory Coast, Ivorians have been abandoning their pets, particularly monkeys, in the fear that they may transmit the virus. Duration: 00:47 Video provided by AFP
Powered by NewsLook.com
Study Links Male-Pattern Baldness To Prostate Cancer

Study Links Male-Pattern Baldness To Prostate Cancer

Newsy (Sep. 16, 2014) New findings suggest men with a certain type of baldness at age 45 are 39 percent more likely to develop aggressive prostate cancer. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins